CHT102 for Advanced Pancreatic Cancer with Mesothelin
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment called CHT102 for people with advanced pancreatic cancer that has a specific protein (mesothelin) on their tumor cells. It's for those who have already tried standard treatments without success or couldn't tolerate them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- Your pancreatic cancer must be advanced or has spread and standard treatments have stopped working or you can't handle them.
- Your tumor cells must test positive for a protein called mesothelin.
- You must have at least one tumor that can be measured on a scan.
- You must be able to take care of yourself (ECOG score 0 or 1) and have good organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called CHT102 for people with advanced solid tumors that have a certain marker (mesothelin). The treatment is for those who haven't responded to standard therapy or who don't have a standard first-line option.
This trial tests a new drug called TMT101 for people with advanced pancreatic cancer or non-small cell lung cancer who have already tried other treatments. The goal is to see if TMT101 is safe and works against the cancer.
This trial tests a new type of cell therapy (CAR-T) that targets two markers on pancreatic cancer cells. It's for people with advanced pancreatic cancer who have already tried standard chemotherapy.
This study tests a new drug called CHT101 for people with advanced solid tumors that have a specific protein (CD70) on the cancer cells. It may be an option if standard treatments have already been tried and failed.
This clinical trial tests an experimental drug called HY05350 for people with advanced solid tumors that have a specific protein (mesothelin). It aims to see if the drug is safe and effective for cancers that have not responded to standard treatments.
This trial tests a new drug (TQB2916) combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for metastatic pancreatic cancer. It aims to see if the combination works better than chemo alone.
Hear when a new Advanced Pancreatic Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.